Benign prostatic hyperplasia (BPH), or an enlarged prostate, is an extremely common condition for men, affecting more than half of all men by age 60 and up to 90% of men by age 80. It is estimated that more than 28 million men in Europe suffer from some form of BPH.

Due to their effectiveness and convenience, prescription BPH medications remain the first line of treatment for the majority of men with BPH. In many men, however, BPH drugs produce undesirable side effects and most do not provide a permanent or curative solution to progressive BPH. To address the limitations of currently available BPH drugs, several promising new BPH drug formulations are expected to gain regulatory approval in Europe within the next 5 years.

In addition to drug therapy, minimally invasive energy-based treatments have been developed that provide moderate-term symptom relief for those patients who do not seek or are not eligible for BPH drug therapy. Minimally invasive BPH therapies include laser-, microwave-, and radiofrequency-based techniques that are performed in an outpatient basis, have short patient recovery times, and are less risky than standard prostate surgery.

The European market for BPH treatment products, including drugs and minimally invasive therapies, was valued at approximately $718.1 million in 2007. Sales of BPH treatment products in Europe are expected to increase at a compound annual rate of 4.5%, reaching an estimated $857.0 million in the year 2011.

This dynamic, new report from Medtech Insight includes analyses of products, current and emerging markets, competitors, and opportunities in the European BPH drugs, devices, and therapies market. Covered topics in this report include a discussion of the healthcare markets of France, Germany, Italy, Spain, the U.K., and the Benelux countries (Belgium, the Netherlands, and Luxembourg); an overview of BPH disorders and treatment options; a comprehensive overview of existing/emerging BPH drugs and clinical trials; minimally invasive BPH therapies including laser-, microwave-, and radiofrequency-based therapies, water-induced thermotherapy; transurethral resection of the prostate (TURP); PK TURP surgery; and temporary/permanent prostatic stents.

Ordering Information

Print versions of Reports are available upon request for an additional fee.

TABLE OF CONTENTS

EXECUTIVE SUMMARY

i.       Symptoms of Benign Prostatic Hyperplasia

ii.      Diagnosis of Benign Prostatic Hyperplasia

iii.      Treatment of Benign Prostatic Hyperplasia

iv.     European Market for Benign Prostatic Drugs, Devices, and Therapies

v.      Methodology

Exhibit ES-1:    The Prostate and Urine Flow

Exhibit ES-2:    Commonly Prescribed Drugs for Benign Prostatic Hyperplasia

Exhibit ES-3:    Europe, Benign Prostatic Hyperplasia Treatment Products, Combined Market Forecast, 2006-2011

1. EUROPEAN HEALTHCARE MARKETS

1.1 The European Union

1.1.1 A Common Currency

1.1.2 Regulatory Policies

1.1.3 Reimbursement

1.1.4 Healthcare Spending

1.2 Selected European National Healthcare Profiles

1.2.1 France

1.2.1.1 Healthcare Organization and Reform

1.2.1.2 Hospital Services

1.2.1.3 Medical Device Reimbursement

1.2.2 Germany

1.2.2.1 Healthcare Organization and Reform

1.2.2.2 Hospital Services

1.2.2.3 Medical Device Reimbursement

1.2.3 Italy

1.2.3.1 Healthcare Organization and Reform

1.2.3.2 Hospital Services

1.2.3.3 Medical Device Reimbursement

1.2.4 Spain

1.2.4.1 Healthcare Organization and Reform

1.2.4.2 Hospital Services

1.2.4.3 Medical Device Reimbursement

1.2.5 United Kingdom

1.2.5.1 Healthcare Organization and Reform

1.2.5.2 Hospital Services

1.2.5.3 Medical Device Reimbursement

1.2.6 Benelux

1.2.6.1 Healthcare Organization and Reform

1.2.6.1.1 Belgium

1.2.6.1.2 Luxembourg

1.2.6.1.3 The Netherlands

1.2.6.2 Hospital Services

1.2.6.3 Medical Device Reimbursement

Exhibit 1-1:      European Union, Medical Devices Risk Classification System

Exhibit 1-2:      2007, Europe, Population Statistics, Selected Countries

Exhibit 1-3:      France, Selected National Healthcare Statistics

Exhibit 1-4:      Germany, Selected National Healthcare Statistics

Exhibit 1-5:      Italy, Selected National Healthcare Statistics

Exhibit 1-6:      Spain, Selected National Healthcare Statistics

Exhibit 1-7:      United Kingdom, Selected National Healthcare Statistics

Exhibit 1-8:      Belgium, Selected National Healthcare Statistics

Exhibit 1-9:      Luxembourg, Selected National Healthcare Statistics

Exhibit 1-10:    The Netherlands, Selected National Healthcare Statistics

2. CLINICAL OVERVIEW OF BENIGN PROSTATIC HYPERPLASIA

2.1 Causes

2.2 Symptoms

2.3 Diagnosis

2.4 Treatment

2.4.1 Prescription Drugs

2.4.2 Minimally Invasive Therapy

2.4.3 Surgery

2.4.4 Stents

Exhibit 2-1:      The Prostate and Urine Flow

Exhibit 2-2:      Commonly Prescribed Drugs for Benign Prostatic Hyperplasia

3. BENIGN PROSTATIC HYPERPLASIA THERAPY PRODUCTS MARKET

3.1 Drug Therapy

3.1.1 Alpha Blockers

3.1.1.1 Cardura/Cardura XL:  Pfizer

3.1.1.2 Flomax:  Astellas Pharma

3.1.1.3 Hytrin:  Abbott Laboratories

3.1.1.4 Xatral:  sanofi-aventis

3.1.1.5 Others

3.1.2 5 Alpha-Reductase Inhibitors

3.1.2.1 Avodart:  GlaxoSmithKline

3.1.2.2 Proscar:  Merck

3.1.3 Emerging Drugs and Investigational Drug Combinations

3.1.3.1 Cetrorelix and Ozarelix:  AEterna Zentaris

3.1.3.2 Cialis:  Eli Lilly

3.1.3.3 Degarelix:  Ferring Pharmaceuticals

3.1.3.4 Dutasteride/Tamsulosin Combination:  GlaxoSmithKline

3.1.3.5 Elocalcitol:  BioXell

3.1.3.6 Etonogestrel:  Organon/Schering-Plough

3.1.3.7 Levitra:  Bayer

3.1.3.8 Naftopidil:  Asahi Kasei

3.1.3.9 NX-1207:  Nymox Pharmaceutical

3.1.3.10 Silodosin:  Kissei Pharmaceutical

3.1.3.11 UK-369003:  Pfizer

3.1.3.12 Zydena:  Dong-A Pharmaceutical

3.1.3.13 Suspended Trials

3.1.4 Alternative Treatments

3.1.4.1 Aspirin

3.1.4.2 Beta Sitosterol

3.1.4.3 Botulinum Toxin Type A

3.1.4.4 Lycopene

3.1.4.5 Pomegranate

3.1.4.6 Pygeum Africanum

3.1.4.7 Saw Palmetto

3.2 Minimally Invasive Therapy

3.2.1 Microwave Thermotherapy

3.2.1.1 CoreTherm System:  ProstaLund

3.2.1.2 Prolieve Thermodilatation System:  Boston Scientific

3.2.1.3 Prostatron and Targis Cooled ThermoTherapy:  Urologix

3.2.1.4 TherMatrx Office Thermo Therapy:  American Medical Systems

3.2.2 Transurethral Needle Ablation/Radiofrequency Therapy

3.2.3 Holmium Laser Ablation/Enucleation of the Prostate

3.2.3.1 VersaPulse PowerSuite:  Lumenis

3.2.4 Interstitial Laser Coagulation

3.2.5 Photoselective Vaporization of the Prostate

3.2.5.1 GreenLight Laser Therapy:  American Medical Systems

3.2.6 Water-Induced Thermotherapy:  Gyrus ACMI/Olympus

3.2.7 Other Energy-Based Technologies

3.3 Prostatic Stents

3.3.1 The Spanner Prostatic Stent:  AbbeyMoor Medical

3.3.2 CoreFlow Soft Stent:  ProstaLund

3.3.3 ProstaPlant Prostate Stent:  ProstaPlant Urology Systems

3.3.4 UroLume Urethral Stent:  American Medical Systems

3.3.5 URO-Stent:  Global Pacific Minerals

3.4 Surgical Treatment

3.4.1 Plasmakinetic Transurethral Resection of the Prostate:  Gyrus ACMI/Olympus

3.5 Market Analysis

3.5.1 Drug Therapy

3.5.1.1 Patient Volumes Forecast

3.5.1.2 Market Forecast

3.5.1.3 Competitive Analysis

3.5.2 Minimally Invasive Therapy

3.5.2.1 Procedure Volumes Forecast

3.5.2.2 Market Analysis

3.5.2.3 Competitive Analysis

3.5.3 Combined Market Forecast

Exhibit 3-1:      2008, Selected Benign Prostatic Hyperplasia Drugs

Exhibit 3-2:      2008, Selected Emerging Benign Prostatic Hyperplasia Drugs

Exhibit 3-3:      Advantages and Disadvantages of Minimally Invasive Therapy

Exhibit 3-4:      2008, Selected Minimally Invasive Benign Prostatic Hyperplasia Therapy Systems

Exhibit 3-5:      ProstaLund’s CoreTherm System

Exhibit 3-6:      The Schelin Catheter

Exhibit 3-7:      The Prostiva Radiofrequency Therapy System

Exhibit 3-8:      Benefits of the Prostiva Radiofrequency Therapy System

Exhibit 3-9:      The VersaPulse PowerSuite Laser System, Holmium Laser Ablation of the Prostate

Exhibit 3-10:    The GreenLight High Performance System

Exhibit 3-11:    Benefits of the GreenLight Laser Therapy System

Exhibit 3-12:    The Spanner Prostatic Stent

Exhibit 3-13:    The CoreFlow Soft Stent

Exhibit 3-14:    Benefits of the UroLume Urethral Stent

Exhibit 3-15:    Advantages of Plasmakinetic Transurethral Resection of the Prostate

Exhibit 3-16:    Europe, Benign Prostatic Hyperplasia Drug Therapy, Patient Volumes Forecast, 2006-2011

Exhibit 3-17:    Europe, Benign Prostatic Hyperplasia Drug Therapy, Market Forecast, 2006-2011

Exhibit 3-18:    2006, Europe, Benign Prostatic Hyperplasia Drug Therapy Market, Share by Supplier

Exhibit 3-19:    2007, Europe, Benign Prostatic Hyperplasia Drug Therapy Market, Share by Supplier

Exhibit 3-20:    Europe, Minimally Invasive Benign Prostatic Hyperplasia Therapy, Procedure Volumes Forecast, 2006-2011

Exhibit 3-21:    Europe, Minimally Invasive Benign Prostatic Hyperplasia Therapy Systems, Market Forecast, 2006-2011

Exhibit 3-22:    2006, Europe, Minimally Invasive Benign Prostatic Hyperplasia Therapy Systems Market, Share by Supplier

Exhibit 3-23:    2007, Europe, Minimally Invasive Benign Prostatic Hyperplasia Therapy Systems Market, Share by Supplier

Exhibit 3-24:    Europe, Benign Prostatic Hyperplasia Treatment Products, Combined Market Forecast, 2006-2011

4. COMPANY PROFILES

4.1       AbbeyMoor Medical, Inc.

4.2       Abbott Laboratories

4.3       AEterna Zentaris, Inc.

4.4       American Medical Systems Holdings, Inc.

4.5       Astellas Pharma, Inc.

4.6       Boehringer Ingelheim GmbH

4.7       Boston Scientific Corporation

4.8       GlaxoSmithKline PLC

4.9       Gyrus ACMI, Inc./Olympus Corporation

4.10     Kissei Pharmaceutical Company LTD

4.11     Lumenis LTD

4.12     Medtronic, Inc.

4.13     Merck & Company, Inc.

4.14     Nymox Pharmaceutical Corporation

4.15     Pfizer, Inc.

4.16     ProstaLund Operations AB

4.17     sanofi-aventis SA

4.18     Spectrum Pharmaceuticals, Inc.

4.19     Urologix, Inc.

APPENDIX:  COMPANY LISTING